<DOC>
	<DOCNO>NCT01188824</DOCNO>
	<brief_summary>The purpose study investigate Safety Efficacy Cilostazol slow progression peripheral arterial disease ( PAD ) ischemic stroke patient PAD Taiwan .</brief_summary>
	<brief_title>The Safety Efficacy Cilostazol Ischemic Stroke Patients With Peripheral Arterial Disease ( SPAD Study )</brief_title>
	<detailed_description>One thousand patient randomized take cilostazol ( 500 patient ) placebo ( 500 patient ) parallel group . Patients screen evaluated Visits 1 assess eligibility prior randomization . The treatment period ( Visit 1-6 ) last 12 month patient receive initial follow-up evaluation ( section 4.5 ) include history physical examination , baseline end treatment ABI carotid IMT assessment . Vascular event death well adverse event include bleed complication also record interval detailed section 4.5 .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>Male female patient , age â‰§50 year ; female patient , postmenopausal ( define least 2 year without menses ) confirm . Ischemic stroke transient ischemic attack patient take aspirin 100 mg , QD Neurologically clinically stable inclusion PAD ( i.e . anklebrachial index ABI &lt; 1.0 ) Patients unable give inform consent Patients history type hemorrhagic stroke ( intracerebral hemorrhage , subarachnoid hemorrhage , others ) Modified Rankin Scale &gt; 4 Patients history dementia require institutional care Known brain tumor Known anemia ( define hemoglobin &lt; 10.0 g/dL ) Known thrombocytopenia ( defined platelet count 100,000/cm3 ) AST ALT &gt; 3 x Upper Normal Limit Calculated creatinine clearance &lt; 30 ml/min accord Copckroft formula ) Known hemostasis coagulation disorder Congestive heart failure , define previous definitive diagnosis , present symptom least Category II NYHA classification system CHF Revascularization low limb artery include bypass surgery , endovascular procedure Symptomatic PAD require treatment cilostazol Known stenosis upper limb artery may affect documentation ABI Patients known hypersensitivity cilostazol</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>